Alnylam Pharmaceuticals Inc (ALNY) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Alnylam Pharmaceuticals Inc   (NASDAQ: ALNY)


Alnylam Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Alnylam Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Alnylam Pharmaceuticals Inc achieved a return on average assets (ROA) of 15.73 % in its second quarter of 2026, this is above ALNY's average return on assets of -24.06%.
Alnylam Pharmaceuticals Inc s assets during the 12 months ending in the second quarter of 2026 are valued at $5 billion

Despite the company's net income deteriorating, Alnylam Pharmaceuticals Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 63 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 510, from total ROA ranking in the first quarter of 2026 at 969.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 21.74 % 22.26 % 23.18 % 20.96 % 19.77 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 808 571 347 77 -286
Return On Assets (TTM) 15.73 % 11.68 % 7.45 % 1.74 % -6.79 %
ALNY's Total Ranking # 510 # 969 # 1923 # 3126 # 3097
Total Assets (TTM) in million 5,559 5,152 4,989 4,852 4,566
Seq. Total Assets Change 7.9 % 3.27 % 2.82 % 6.26 % 8.36 %
Seq. Net Income Change -20.15 % 10.5 % -25.75 % - -

ALNY's 5 Years Annual ROA >> Back to ALNY Management Effectiveness >> Compare ALNY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 31
Sector # 64
Overall # 324

Return On Assets Statistics
High Average Low
15.76 %
-24.06 %
-54.94 %
(Jun 30 2026)   (Mar 31 2014)



  News about Alnylam Pharmaceuticals Inc Return on Assets ROA

Alnylam Pharmaceuticals Unveils Promising Data on Vutrisiran for ATTR Amyloidosis with Cardiomyopathy at HFSA Annual ...

In a significant advancement in the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) recently showcased compelling findings from the HELIOS-B Phase 3 clinical study of vutrisiran. This investigational RNA interference (RNAi) therapeutic was highlighted during the Late Breaking Clinical Research Session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which took place virtually. The HELIOS-B study represents a landmark in the ongoing effort to address the complexities of ATTR-CM, a severe condition often marked by progressive heart failure linked to the accumulation of amyloid proteins. Results discussed during the session demonstrated that vutrisiran met its primary endpoint, reflecting its considerable potential to mitigate cardiac challenges associated with this condition. The presentation ignited interest among cardiologists and researchers, underscoring the critical need for effective treatments that not only address disease symptoms but also target the underlying pathology of amyloidosis.Looking ahead, Alnylam is set to continue its momentum, with plans to present detailed results of the HELIOS-B study at the European Society of Cardiology (ESC) Congress 2024, scheduled for August 30 to September 2 in London, UK. This platform will provide an opportunity to delve deeper into the data and engage with a global audience, further enhancing the visibility and relevance of vutrisiran within the cardiovascular therapeutic landscape. The prospect of revealing additional insights at such a prestigious gathering amplifies the anticipation surrounding the treatment s future.



Financial Statements
Alnylam Pharmaceuticals Inc 's Assets $ 5,559 million ALNY's Balance sheet
Alnylam Pharmaceuticals Inc 's Income $ 164 million Quarterly ALNY's Income Statement
ALNY's Income by Division See ALNY's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 23.18 % 11.53 % 8.97 % -2.41 % 7.79 %
Total Assets in million 4,989 4,050 3,631 3,332 3,414
Y / Y Net Income Change - - - - -
Net Income in million 314 -278 -440 -1,131 -853
Annual Return On Assets 6.29 % -6.87 % -12.12 % -33.95 % -24.98 %

ALNY's 5 Years Annual ROA >> Back to ALNY Management Effectiveness >> Compare ALNY ROA to its Competitors



Comment on ALNY's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 6.29 % compared to prior year, due to annual net income growth of % to $313.75 million, while value of Alnylam Pharmaceuticals Inc 's overall assets grew just by 23.18 % to $4,988.50 million, compared to $4,988.50 a year before.


More Return On Assets Ratios
ALNY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALNY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALNY's Competitors
Subscribers only: Roa for Alnylam Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ALNY's Customers

You may also want to know
ALNY's Roi ALNY's Inventory Turnover Ratio ALNY's Growth Rates ALNY's Dividend Comparisons
ALNY's Profitability Ratios ALNY's Asset Turnover Ratio ALNY's Dividend Growth
ALNY's Roe ALNY's Valuation Ratios ALNY's Financial Strength Ratios ALNY's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %

Date modified: 2026-09-14T03:47:53+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.